Evidence map›Paper›PMID 32666389›Full record

ArticleInternational journal of clinical oncology2020

Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.

Shintaro Nakano, Satoshi Yuki, Yasuyuki Kawamoto, Hiroshi Nakatsumi, Takayuki Ando, Shinya Kajiura, Ayumu Yoshikawa, Kazuaki Harada, Kazuteru Hatanaka, Aya Tanimoto and 6 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Correlation ofJournal of clinical medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Shintaro NakanoDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan.
Satoshi YukiDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan.
Yasuyuki KawamotoDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan.
Hiroshi NakatsumiDivision of Cancer Center, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan.
Takayuki AndoDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630, Sugitani, Toyama-shi, Toyama, 930-0194, Japan.
Shinya KajiuraDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, 2630, Sugitani, Toyama-shi, Toyama, 930-0194, Japan.
Ayumu YoshikawaDepartment of Medical Oncology, Kushiro Rosai Hospital, 13-23 Nakazono-cho, Kushiro, Hokkaido, 085-8533, Japan.
Kazuaki HaradaDepartment of Medical Oncology, Kushiro Rosai Hospital, 13-23 Nakazono-cho, Kushiro, Hokkaido, 085-8533, Japan.
Kazuteru HatanakaDepartment of Gastroenterology, Hakodate Municipal Hospital, 1-10-1 Minatomachi, Hakodate, Hokkaido, 041-8680, Japan.
Aya TanimotoDepartment of Medical Oncology, Teine Keijinkai Hospital, 1-40, Maeda1-12, Teine-Ku, Sapporo, Hokkaido, 006-8555, Japan.
Atsushi IshiguroDepartment of Medical Oncology, Teine Keijinkai Hospital, 1-40, Maeda1-12, Teine-Ku, Sapporo, Hokkaido, 006-8555, Japan.
Takuya HondaDivision of Clinical Oncology Center, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki, 852-8501, Japan.
Masayoshi DazaiDepartment of Gastroenterology, Sapporo Medical Center NTT EC, Minami1, Nishi5, Chuo-Ku, Sapporo, Hokkaido, 060-0061, Japan.
Takahide SasakiDepartment of Internal Medicine, Hokkaido Gastroenterology Hospital, 2-10, Honcho1-1, Higashi-Ku, Sapporo, Hokkaido, 065-0041, Japan.
Naoya SakamotoDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan.
Yoshito KomatsuDivision of Cancer Center, Hokkaido University Hospital, Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido, 060-8648, Japan. ykomatsu@ac.cyberhome.ne.jp.ORCID http://orcid.org/0000-0002-1570-6802
Hokkaido University Hospital · JPKushiro Rosai Hospital · JPTeine Keijinkai Hospital · JPUniversity of Toyama · JPHakodate National Hospital · JPHokkaido hospital · JPNagasaki University Hospital · JPNTT Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is unclear whether the UGT1A1 status, single heterozygous (SH) or wild type (WT), is associated with the efficacy and toxicity of irinotecan monotherapy in advanced gastric cancer (AGC). We investigated the association between clinical outcomes (efficacy and safety) and UGT1A1 status in patients who received irinotecan monotherapy.

methodsWe evaluated AGC patients who received irinotecan monotherapy between January 2011 and December 2017. Efficacy was assessed according to overall survival (OS) and progression-free survival (PFS). Toxicity was graded using the Common Toxicity Criteria for Adverse Events (version 4.0).

resultsA total of 100 patients were evaluated (62 and 38 patients with UGT1A1 WT and SH, respectively). In the WT and SH groups, the irinotecan dose was reduced in 19 (30.6%) and 18 (47.2%) patients (p = 0.135), respectively; treatment was delayed due to adverse events (AEs) in 19 (30.6%) and 13 (34.2%) patients (p = 0.826), respectively; the median PFS was 3.15 and 3.25 months (HR, 0.734; 95% CI 0.465-1.158; p = 0.184), respectively; and the median OS was 10.4 and 7.26 months (HR, 1.137; 95% CI 0.752-1.721; p = 0.543), respectively. Severe hematological AEs (Grade ≥ 3) were significantly more frequent in the SH group than in the WT group (63% vs. 36%; p = 0.008), while severe non-hematological AEs was not significantly different (16.0% vs. 6.5%; p = 0.173).

conclusionThere was no significant difference in the efficacy of irinotecan monotherapy between UGT1A1 WT and UGT1A1 SH, but UGT1A1 SH was associated with a high frequency of severe hematological toxicity.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleGlucuronosyltransferaseHeterozygoteHumansIrinotecanMaleMiddle AgedPlatinum CompoundsPyrimidinesRetrospective StudiesStomach NeoplasmsTreatment Outcome5-fluoropyrimidineGlucuronosyltransferaseIrinotecanPlatinum CompoundsPyrimidinesUGT1A1 EnzymeGastric cancerIrinotecanUGT1A1

Identifiers

PMID32666389
PMCPMC7498487
OpenAlexW3043077376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.